Aided by capital from SVF, Shilpa has doubled its manufacturing capacity and acquired an Austria-based pharma business in recent years. This growth has allowed SVF to make a 400 per cent return on its investment.
Shilpa has used the investment to strengthen its position in the oncology active pharmaceutical ingredient (API) market. It has also expanded its contract research and manufacturing services (CRAMS) business in recent years, leading to it exporting to the US, Europe and Japan.
